Multicenter retrospective analysis regarding the clinical manifestations and treatment results in patients with hairy cell leukemia: twenty-four year Turkish experience in cladribine therapy.
In this multicenter retrospective analysis, we aimed to present clinical, laboratory and treatment results of 94 patients with Hairy cell leukemia diagnosed in 13 centers between 1990 and 2014. Sixty-six of the patients were males and 28 were females, with a median age of 55. Splenomegaly was present in 93.5% of cases at diagnosis. The laboratory findings that came into prominence were pancytopenia with grade 3 bone marrow fibrosis. Most of the patients with an indication for treatment were treated with cladribine as first-line treatment. Total and complete response of cladribine was 97.3% and 80.7%. The relapse rate after cladribine was 16.6%, and treatment related mortality was 2.5%. Most preferred therapy (95%) was again cladribine at second-line, and third line with CR rate of 68.4% and 66.6%, respectively. The 28-month median OS was 91.7% in all patients and 25-month median OS 96% for patients who were given cladribine as first-line therapy. In conclusion, the first multicenter retrospective Turkish study where patients with HCL were followed up for a long period has revealed demographic characteristics of patients with HCL, and confirmed that cladribine treatment might be safe and effective in a relatively large series of the Turkish study population.
Pamukkale University, Department of Hematology, Denizli, Turkey.
Sibel
S
Hacioglu
Ataturk University, Department of Hematology, Erzurum, Turkey.
Yusuf
Y
Bilen
Marmara University, Department of Hematology, Istanbul, Turkey.
Ali
A
Eser
Erciyes University, Department of Hematology, Kayseri, Turkey.
Serdar
S
Sivgin
Cukurova University, Department of Hematology, Adana, Turkey.
Emel
E
Gurkan
Ataturk University, Department of Hematology, Erzurum, Turkey.
Rahsan
R
Yildirim
Celal Bayar University, Department of Hematology, Manisa, Turkey.
Ismet
I
Aydogdu
Pamukkale University, Department of Hematology, Denizli, Turkey.
Mehmet Hilmi
MH
Dogu
Gaziantep University, Department of Hematology, Gaziantep, Turkey.
Mehmet
M
Yilmaz
Ankara Oncology Education and Research Hospital, Department of Hematology, Ankara, Turkey.
Omur
O
Kayikci
Mersin University, Department of Hematology, Mersin, Turkey.
Anil
A
Tombak
Inonu University, Department of Hematology, Malatya, Turkey.
Irfan
I
Kuku
Diskapi Yildirim Beyazit Education and Research Hospital, Department of Hematology, Ankara, Turkey.
Harika
H
Celebi
Osmangazi University, Department of Hematology, Eskisehir, Turkey.
Meltem Olga
MO
Akay
Yuzuncu Yil University, Department of Hematology, Van, Turkey.
Ramazan
R
Esen
Cumhuriyet University, Department of Hematology, Sivas, Turkey.
Serdal
S
Korkmaz
Pamukkale University, Department of Hematology, Denizli, Turkey.
Ali
A
Keskin
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017338:Cladribine / Q000008:administration & dosage / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007943:Leukemia, Hairy Cell / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016019:Survival Analysis; D014421:Turkey
D000970:Antineoplastic Agents; D017338:Cladribine
Turkey; cladribin; hairy cell leukemia; survival; treatment